Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

The proliferative capacity of residual breast cancer (BC) disease indicates the existence of partial treatment resistance and higher probability of tumor recurrence. We explored the therapeutic potential of adding neoadjuvant metformin as an innovative strategy to decrease the proliferative potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Bonet, Eugeni, Buxó, Maria, Cuyàs, Elisabet, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A., Amillano, Kepa, Domínguez, Severina, Luque, Maria, Morilla, Idoia, Stradella, Agostina, Viñas, Gemma, Cortés, Javier, Oliveras, Gloria, Meléndez, Cristina, Castillo, Laura, Verdura, Sara, Brunet, Joan, Joven, Jorge, Garcia, Margarita, Saidani, Samiha, Martin-Castillo, Begoña, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947627/
https://www.ncbi.nlm.nih.gov/pubmed/31835708
http://dx.doi.org/10.3390/jcm8122180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947627/
https://www.ncbi.nlm.nih.gov/pubmed/31835708
http://dx.doi.org/10.3390/jcm8122180

Ejemplares similares